BCL2 and neoplasm: Bcl-2 expression was lost in 70 % of the most aggressive triple-negative BC cases, i.e. those lacking ERα, PgR and Her-2, and was significantly associated with high proliferation, tumor progression and increased risk of death and recurrence [48].